Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + vindesine + dacarbazine
- Development stage
- Phase 4
- Lead developer
- Michigan State University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination is used in chemotherapy, primarily for treating advanced cancers such as malignant melanoma and lung carcinoma. **Cisplatin** is a platinum-based antineoplastic drug that works by cross-linking DNA, which interferes with cell division. **Vindesine** is a vinca alkaloid that inhibits microtubule assembly, disrupting cell division. **Dacarbazine** is an alkylating agent that damages DNA, preventing cancer cells from reproducing.
02
Targets
DNAMicrotubule
Beyond the preview
Go deeper on cisplatin + vindesine + dacarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + vindesine + dacarbazine.